Inaktiver Wert

Raptor Pharmaceutical Corp Aktie

Aktien

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

Depomed : Le laboratoire Depomed résigné à se vendre-sources	16.09.16
Exclusive: Drugmaker Depomed prepares to explore a sale - sources	15.09.16
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information	15.09.16
Raptor Pharmaceutical : Acquisition May Not Be in the Best Interests of RPTP Shareholders	14.09.16
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information	12.09.16

Manager	Titel	Alter	Seit
Paul Hoelscher DFI	Director of Finance/CFO	59	25.10.16
Kim Lee IRC	Investor Relations Contact	-	23.10.14
Françoise de Craecker PRN	Corporate Officer/Principal	62	-

Aufsichtsräte	Titel	Alter	Seit
Gregg Lapointe CHM	Chairman	65	01.01.15
Timothy Walbert BRD	Director/Board Member	57	11.04.11
Paul Hoelscher DFI	Director of Finance/CFO	59	25.10.16

Sektor

	% 1. Jan.	Kap.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31 %	103 Mrd.
REGENERON PHARMACEUTICALS, INC.	+0,56 %	95,28 Mrd.
ARGENX SE	+1,69 %	22,15 Mrd.
BIONTECH SE	-17,37 %	21,02 Mrd.
GENMAB A/S	-9,30 %	18,15 Mrd.
WUXI APPTEC CO., LTD.	-41,01 %	16,73 Mrd.
BEIGENE, LTD.	-14,85 %	16,05 Mrd.
NEUROCRINE BIOSCIENCES, INC.	+3,21 %	13,68 Mrd.
SAREPTA THERAPEUTICS, INC.	+33,54 %	12,17 Mrd.